Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alirocumab in Healthy Chinese Subjects: A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study

BACKGROUND: The addition of alirocumab (a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 [PCSK9]) to background statin therapy provides significant incremental low-density lipoprotein cholesterol (LDL-C) lowering and cardiovascular event risk reduction. OBJECTIVES:...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Haiyan, Wei, Yudong, Yang, Zhenhua, Zhang, Shuang, Xu, Xiuxiu, Shuai, Mengmeng, Vitse, Olivier, Wu, Yiwen, Baccara-Dinet, Marie T., Zhang, Yi, Li, Jianyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7548281/
https://www.ncbi.nlm.nih.gov/pubmed/32080823
http://dx.doi.org/10.1007/s40256-020-00394-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7548281/
https://www.ncbi.nlm.nih.gov/pubmed/32080823
http://dx.doi.org/10.1007/s40256-020-00394-1

Ejemplares similares